Long-term persistence of cellular immunity to Oka vaccine virus induced by pernasal co-administration with Escherichia coli enterotoxin in mice

Kamiya, Naoki; Asano, Yoshizo; Yoshino, Junji; Sasaki, Keiko; Honma, Yasuko; Kawase, H; Yokochi, Takashi; Shiraki, Kimíyasu; Tsuji, Takao

doi:10.1016/s0264-410x(01)00032-9

Cited by 8 publications

(10 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, both toxins can act as adjuvants for the enhancement of mucosal and serum antibody responses to a mucosal co-administered antigen, resulting in a long-term memory to this antigen [35,105,202]. The immune response that is occurring against these toxins is not an advantage.…”

Section: Cholera Toxin and Escherichia Coli Thermolabile Enterotoxinmentioning

confidence: 99%

Adjuvants modulating mucosal immune responses or directing systemic responses towards the mucosa

et al. 2006

View full text Add to dashboard Cite

-In developing veterinary mucosal vaccines and vaccination strategies, mucosal adjuvants are one of the key players for inducing protective immune responses. Most of the mucosal adjuvants seem to exert their effect via binding to a receptor/or target cells and these properties were used to classify the mucosal adjuvants reviewed in the present paper: (1) ganglioside receptor-binding toxins (cholera toxin, LT enterotoxin, their B subunits and mutants); (2) surface immunoglobulin binding complex CTA1-DD; (3) TLR4 binding lipopolysaccharide; (4) TLR2-binding muramyl dipeptide; (5) Mannose receptor-binding mannan; (6) Dectin-1-binding ß 1,3/1,6 glucans; (7) TLR9-binding CpG-oligodeoxynucleotides; (8) Cytokines and chemokines; (9) Antigen-presenting cell targeting ISCOMATRIX and ISCOM. In addition, attention is given to two adjuvants able to prime the mucosal immune system following a systemic immunization, namely 1α, 25(OH) 2 D 3 and cholera toxin.

show abstract

Section: Cholera Toxin and Escherichia Coli Thermolabile Enterotoxinmentioning

confidence: 99%

Adjuvants modulating mucosal immune responses or directing systemic responses towards the mucosa

et al. 2006

View full text Add to dashboard Cite

show abstract

“…One month after the BALB/c mice had been immunized once pernasally with the live vaccine (200 pfu) with or without each toxin (10 mg), the spleen cells from three mice were prepared in Moor's RPMI-1640 containing 10% FCS and 10 U/ml heparin and were mixed. As described previously Kamiya et al, 2001], we determined the concentration of cytokine after 48-hr stimulation, which yielded the highest release, to detect the difference in cytokine concentration between with and without stimulation of VZV in vitro. The spleen cells (1 Â 10 7 /ml) were stimulated for 48 hr with or without the Oka vaccine; the concentrations of interleukin-2 and -4 (IL-2 and IL-4) in the culture supernatant were then determined by the enzyme-linked immunosorbent assay (ELISA).…”

Section: Il-2 and Il-4 Production By Spleen Cells From Mice Immunizedmentioning

confidence: 99%

“…However, cellular immunity was induced by a single coadministration and persisted for more than 12 months. The heat-labile enterotoxin induces both Th1-and Th2-type helper T-cell responses to an antigen, but the former response predominates on exposure to the Oka vaccine Kamiya et al, 2001]. It has been reported that cholera toxin and its B subunit also induce both Th1-and Th2-type helper T-cell responses to some antigens [Tamura et al, 1988;Kikuta et al, 1990;Xu-Amano et al, 1993;Hornquist and Lycke, 1993;Bowen et al, 1994].…”

Section: Introductionmentioning

confidence: 99%

Live varicella vaccine polarizes the mucosal adjuvant action of cholera toxin or its B subunit on specific Th1‐type helper T cells with a single nasal coadministration in mice

Sasaki¹,

Kato²,

Takahashi³

et al. 2003

Journal of Medical Virology

Self Cite

View full text Add to dashboard Cite

This study was undertaken to determine whether the specific Th1- or Th2-cell response to varicella-zoster virus was induced predominantly by a mucosal adjuvant, cholera toxin, in mice. A commercially available live varicella vaccine (Oka strain) and cholera toxin or its B subunit were administered simultaneously via the nasal route. Delayed-type hypersensitivity to the Oka vaccine was induced, but the systemic neutralizing antibody response was low. The delayed-type hypersensitivity evoked after a single administration was relatively higher than that on administration three times. When spleen cells from mice immunized once with the vaccine and cholera toxin or its B subunit were restimulated with the live vaccine in vitro, there was greater thymidine uptake and production of interleukin- 2 (IL-2) than controls, but only a low level of IL-4 production. The production of IL-2 induced by the B subunit of cholera toxin was less than that by cholera toxin and a mutant of Escherichia coli enterotoxin on co-immunization with the vaccine in mice. Cholera toxin and its B subunit have been reported to induce predominantly a specific Th2-type T-cell response to various antigens. However, the Oka vaccine is an antigen that polarizes the activation of specific Th1/Th2-type T cells by cholera toxin or its B subunit to the Th1-type side. Cholera toxin and its B subunit are thus useful mucosal adjuvants for inducing cellular immunity to the Oka vaccine similar to Escherichia coli enterotoxin.

show abstract

“…It is well known that bacterial holotoxins such as cholera toxin act as strong adjuvants for induction of mucosal and serum antibodies against an antigen [3]. In addition, CTB, which has no enzymatic activity but has GM1-binding properties, can also serve as an adjuvant for antigens administered by an intranasal route [19].…”

Section: Comparison Of Adjuvant Activity Of Omls To That Of Cholera Tmentioning

confidence: 99%

“…Therefore, induction of an effective mucosal immune response by vaccination is of considerable importance, and adjuvants and delivery systems are particularly important for this purpose since most antigens are poorly immunogenic when given via mucosal (oral or nasal) routes. Bacterial holotoxins such as cholera toxin and E. coli thermolabile enterotoxin can act as adjuvants for induction of mucosal and serum antibodies against an antigen when co-administered with the antigen mucosally, resulting in long-term memory to the antigens [3,4], but their use is restricted by toxicity [5][6][7]. CpG oligonucleotides (ODNs), which are recognized by Toll-like receptor (TLR)-9 expressed on antigen-presenting cells (APCs), are also potent mucosal adjuvants that significantly enhance cellular and humoral responses to co-administered antigens when given parenterally or mucosally [8,9].…”

Section: Introductionmentioning

confidence: 99%

Mucosal adjuvant activity of oligomannose-coated liposomes for nasal immunization

Ishii

Kojima

2009

Glycoconj J

View full text Add to dashboard Cite

In the present study, we investigated the effectiveness of liposomes coated with a neoglycolipid consisting of mannotriose and dipalmitoylphosphatidylcholine (Man3-DPPE) as an adjuvant for induction of mucosal immunity. Immunization of BALB/c mice with ovalbumin (OVA)-encapsulated Man3-DPPE-coated liposomes (oligomannose-coated liposomes; OMLs) by a nasal route produced high levels of OVA-specific IgG and IgA antibodies in serum of immunized mice 1 week after the last nasal immunization, whereas no significant serum antibody responses were observed in mice that received OVA in uncoated liposomes or OVA alone. Seven weeks after the last nasal immunization, nasal challenge with an excess amount of OVA in mice that had received OVA/OMLs led to an anamnestic response to the antigen that resulted in 5- to 10-fold increases of antigen-specific serum IgG and IgA antibodies. Only mice immunized nasally with OML/OVA secreted antigen-specific secretory IgA in nasal washes and produced interferon-gamma secreting cells in nasopharyngeal-associated lymphoreticular tissue. Taken together, these results show that nasal administration of OMLs induces mucosal and systemic immunity that are specific for the entrapped antigen in the liposomes. Thus, liposomes coated with synthetic neoglycolipids might be useful as adjuvants for induction of mucosal immunity.

show abstract

Long-term persistence of cellular immunity to Oka vaccine virus induced by pernasal co-administration with Escherichia coli enterotoxin in mice

Cited by 8 publications

References 20 publications

Adjuvants modulating mucosal immune responses or directing systemic responses towards the mucosa

Adjuvants modulating mucosal immune responses or directing systemic responses towards the mucosa

Live varicella vaccine polarizes the mucosal adjuvant action of cholera toxin or its B subunit on specific Th1‐type helper T cells with a single nasal coadministration in mice

Mucosal adjuvant activity of oligomannose-coated liposomes for nasal immunization

Contact Info

Product

Resources

About